Skip to content

Insulet PODD Contract with Customer, Liability

Contract with Customer, Liability at other companies

Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's contract with customer, liability?
Insulet (PODD) reported contract with customer, liability of $14M in Q1 2026.
How has Insulet's contract with customer, liability changed year-over-year?
Insulet's contract with customer, liability decreased by 13.0% year-over-year, from $16.1M to $14M.
What is the long-term trend for Insulet's contract with customer, liability?
Over 4 years (2021 to 2025), Insulet's contract with customer, liability has grown at a 32.7% compound annual growth rate (CAGR), from $5M to $15.5M.